An­nal­isa Jenk­in­s' next ca­reer chap­ter takes her back to Eu­rope

An­nal­isa Jenk­ins has worked at quite a few places. Be­fore she was the leader of the gene ther­a­py play­er Di­men­sion — bought out by Ul­tragenyx $RARE af­ter a set­back on the lead pro­gram — she has held glob­al R&D po­si­tions at Bris­tol-My­ers Squibb $BMY and Mer­ck Serono af­ter leav­ing the British Roy­al Navy. And each of­fered some­thing that the oth­er couldn’t ex­act­ly re­place.

“One thing I missed at Di­men­sion, and that I was look­ing to again, was to be­come more of a glob­al leader, which was what I loved so much when I was at Big Phar­ma,” Jenk­ins said. “But what I didn’t want to lose was the ag­ile, re­al­ly fast paced en­tre­pre­neur­ial side of the small­er biotechs, which I have so en­joyed and gives me so much en­er­gy, and which you don’t get at phar­ma.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER